Relief Therapeutics Holding SA's (OTC:RLFTF) collaborating partner NRx Pharmaceuticals Inc (NASDAQ:NRXP) has announced that the FDA has denied Breakthrough Therapy Designation for aviptadil.

NRx noted that though the designation is not required for drug approval or emergency use authorization, but can afford faster review times, the ability to submit a rolling application, and dedicated FDA review personnel.
Related content: Benzinga's Full FDA Calendar.
Additionally, according to the CEO Update, the FDA has already granted priority and rolling review as part of the Fast Track Designation awarded in July 2020.
Therefore, the denial does not impede NRx's ability to seek drug approval.
Relief's lead drug candidate, RLF-100 (aviptadil), is a synthetic form of Vasoactive Intestinal Peptide (VIP).
It is in late-stage clinical testing in the U.S. for respiratory deficiency due to COVID-19.
Related Link: NRx Pharma's COVID-19 Candidate Receives FDA Review For Manufacturing Information.
Price Action: NRXP shares closed 5.56% lower at $4.25 during after-hours trading on Tuesday.

Relief Therapeutics Stock News

News